Your Messages Inbox
Your Article Summary
See Latest ArticlesAngiotech pharmaceuticals announces fda approval of nextgeneration taxus liberte atom stent
Angiotech Pharmaceuticals, 05/28/09
Angiotech Pharmaceuticals, Inc. announced that its corporate partner, Boston Scientific Corporation has received approval from the U.S. Food and Drug Administration to market its TAXUS Liberte Atom Paclitaxel-Eluting Coronary Stent System, a highly deliverable, next-generation drug-eluting stent specifically designed for treating small coronary vessels. It was approved for use in vessels as small as 2.25 mm in diameter and joins the TAXUS Express Atom Stent as the only drug-eluting stents approved for small vessel use in the U.S. The Company plans to begin a full U.S. launch of TAXUS Liberte Atom next month.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Cell Therapeutics Announces FDAs Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma, February 2010
Cell Therapeutics, 12/18/09
Eslicarbazepine: A novel antiepileptic agent designed for improved efficacy and safety
Formulary , 12/16/09
Human genome sciences announces submission of marketing authorization application to emea for joulferon
Human Genome Sciences, 12/16/09
Today in Medical Devices/Products...keeping you current
Receive free subspecialty "5-minute updates" via email
Covidien Announces Definitive Agreement to Sell U.S. Radiopharmacies
Covidien, 12/18/09
Eslicarbazepine: A novel antiepileptic agent designed for improved efficacy and safety
Formulary , 12/16/09
FDA Advisory Committee Supports Use of Aztreonam for Inhalation Solution for Patients with Cystic Fibrosis
Gilead, 12/14/09
Article Search
Sponsor